© 2022 MJH Life Sciences and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
© 2022 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Healthcare specialists provide their insight in the context of a patient’s journey with thyroid cancer, highlighting treatment options that make up today’s therapeutic landscape.
March 31st 2022
Health care specialists provide an overview on the nature of differentiated thyroid cancer and discuss subtypes of disease that patients may present with.
Expert perspectives on the broad management of differentiated thyroid cancer, including surgery, radiation treatment, and systemic therapy.
April 7th 2022
Considerations for the role of patient advocacy groups and patient-to-patient education in the differentiated thyroid cancer journey.
Jim Lesniak shares his experience of receiving a diagnosis of and being treated for differentiated thyroid cancer.
April 14th 2022
Expert perspectives on the process of surgery and radiation therapy used for less severe cases of differentiated thyroid cancer.
Discussion on when differentiated thyroid cancer is determined to be iodine-refractory, and how patients should be followed in this setting.
April 21st 2022
Health care specialists share insight on the work-up of patients with iodine-refractory differentiated thyroid cancer and how this may affect systemic therapy options.
Expert and patient perspectives on receiving lenvatinib therapy for iodine-refractory differentiated thyroid cancer.
April 28th 2022
Considerations for how dosing and dose reductions can be used to optimize use of lenvatinib for iodine-refractory DTC.
Discussion on how best to communicate with care providers while undergoing therapy for iodine-refractory differentiated thyroid cancer.
May 5th 2022
Shared practical advice for patients who may be undergoing treatment for iodine-refractory differentiated thyroid cancer.
A brief discussion on therapeutic options one may consider after progression on lenvatinib therapy for iodine-refractory DTC.
May 12th 2022
Before closing out their discussion on differentiated thyroid cancer, patients and health care professionals alike consider unmet needs in this space.
From Hair Loss to Menopause, a Look at the ‘Good Stuff’ From Cancer Treatment
Bringing Clarity to Ocular Melanoma: Patient Advocate Offers Ways Support Can Help Patients, Loved Ones
FDA Approves Lytgobi for Advanced Cholangiocarcinoma
Novel Drug Decreases Fibrosis in Myelofibrosis, A Type of Blood Cancer